A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMCF106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date27/09/23 → 27/09/26

Keywords

  • clinical trial
  • Advanced PRAME-Positive Cancers
  • oncology
  • Metastatic Cancer

Clinical Trial Phase

  • Phase I
  • Phase II